GleamWall
中文EN

RNXT RenovoRx, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1574094 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-17.2%
TTM EPS YoY13.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin84.0%
Operating margin-489.0%
Net margin-469.0%
FCF margin-440.4%
EBITDA margin-416.6%

Returns

ROE-150.0%
ROA-110.1%
ROIC (approx.)—
Asset turnover0.23x

Leverage & solvency

Liabilities / assets25.4%
Debt / equity0.00x
Current ratio5.65x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.93x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue3.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$1.07M$909,000$563,000$238,000$266,000$422,000$197,000—
Cost of revenue$188,000$143,000$84,000$28,000$53,000$152,000$94,000—
Gross profit$878,000$766,000$479,000$210,000$213,000$270,000$103,000—
R&D expense$1.24M$1.20M$1.23M$1.50M$1.69M$1.43M$1.64M$1.58M
SG&A expense$2.87M$2.92M$2.72M$2.23M$1.73M$1.52M$1.57M$1.10M
Operating income-$3.24M-$3.35M-$3.47M-$3.52M-$3.20M-$2.68M-$3.11M-$2.63M
Income tax$0$0$0$2,000$0$0$0—
Net income-$3.65M-$2.91M-$3.52M-$2.94M-$2.91M-$2.90M-$2.42M-$2.88M
EBITDA-$3.23M-$3.34M-$3.47M-$1.52M-$2.20M-$1.68M-$3.11M—
EPS (basic)-0.08-0.06-0.09—-0.08-0.08-0.08—
EPS (diluted)-0.08-0.06-0.09—-0.08-0.08-0.08—
Weighted avg. shares (diluted)48.19M47.30M38.03M—36.65M36.58M31.40M—
Balance sheet
Cash & equivalents$10.40M$9.48M$12.36M$7.02M$10.04M$12.31M$14.58M$7.15M
Receivables$609,000$480,000$280,000$139,000$169,000$363,000$242,000$43,000
Inventory$341,000$383,000$379,000$189,000$272,000——$0
Current assets$11.81M$10.81M$13.72M$7.89M$10.98M$13.39M$15.74M$7.83M
PP&E, net$89,000$94,000$77,000$12,000$13,000$13,000$13,000$12,000
Total assets$12.44M$11.47M$13.96M$8.10M$11.21M$13.64M$16.01M$8.12M
Current liabilities$2.09M$1.88M$1.92M$1.96M$1.88M$1.56M$1.74M$1.91M
Total liabilities$3.15M$2.49M$2.70M$2.67M$3.13M$3.00M$2.86M$3.64M
Shareholders' equity$9.28M$8.98M$11.27M$5.42M$8.08M$10.64M$13.16M$4.48M
Shares outstanding48.19M45.12M45.05M36.61M36.65M36.65M36.55M24.03M
Cash flow statement
Operating cash flow-$2.54M-$2.87M-$3.71M-$3.02M-$2.27M-$2.30M-$3.38M-$2.43M
Capital expenditure$19,000$71,000$0$0$0$0$2,000—
Free cash flow-$2.56M-$2.94M-$3.71M-$3.02M-$2.27M-$2.30M-$3.38M—
Investing cash flow-$19,000-$71,000$0$0$0$0-$2,000—
Financing cash flow$3.48M$55,000$9.05M$0$0$34,000$10.81M$33,000
Depreciation & amortization$5,000$5,000$1,000$2.00M$1.00M$1.00M$1,000—
Stock-based compensation$469,000$570,000$317,000$285,000$349,000$345,000$288,000$252,000

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.